key: cord-0847467-4mjrpjit authors: Levine-Tiefenbrun, M.; Yelin, I.; Katz, R.; Herzel, E.; Golan, Z.; Schreiber, L.; Wolf, T.; Nadler, V.; Ben-Tov, A.; Kuint, J.; Gazit, S.; Patalon, T.; Chodick, G.; Kishony, R. title: Decreased SARS-CoV-2 viral load following vaccination date: 2021-02-08 journal: nan DOI: 10.1101/2021.02.06.21251283 sha: 3cec56ef7834aa539ff6d4e70ee3c8ab41139ff1 doc_id: 847467 cord_uid: 4mjrpjit Beyond their substantial protection of individual vaccinees, it is hoped that the COVID-19 vaccines would reduce viral load in breakthrough infections thereby further suppress onward transmission. Here, analyzing positive SARS-CoV-2 test results following inoculation with the BNT162b2 mRNA vaccine, we find that the viral load is reduced 4-fold for infections occurring 12-28 days after the first dose of vaccine. These reduced viral loads hint to lower infectiousness, further contributing to vaccine impact on virus spread. ). Analyzing infection Ct values over time, we find that mean viral load substantially decreased 12 days post-vaccination, coinciding with the known onset of the early vaccine protection 1 . Calculating the mean Ct values for post-vaccination infections identified on each day following vaccination, we found that Ct values of positive samples collected 12-28 days after vaccination were higher than Ct values of positive samples taken during the first 11 days following vaccination ( Figure 1 for RdRp, Extended Data Fig. 1 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 8, 2021. ; https://doi.org/10.1101/2021.02.06.21251283 doi: medRxiv preprint equivalent to a factor of about 1.94 in viral particles per sample 10 , these Ct differences represent a viral load ratio ranging from 2.96 to 4.68. Our results show that infections occurring 12 days or longer following vaccination have significantly reduced viral loads, potentially affecting viral shedding and contagiousness as well as severity of the disease 11 . Our report is based on an observational study, not a randomized controlled trial, and has several associated limitations: (1) The group of vaccinees may differ from the demographically-matched control group in ways which could affect the observed viral load, such as behaviour, tendency to get tested, and general health status. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted February 8, 2021. ; https://doi.org/10.1101/2021.02.06.21251283 doi: medRxiv preprint Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine The effectiveness of the first dose of BNT162 b 2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: real-world evidence Indirect benefits are a crucial consideration when evaluating SARS-CoV-2 vaccine candidates SARS-CoV-2 Vaccination -An Ounce (Actually, Much Less) of Prevention A guide to vaccinology: from basic principles to new developments SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn Understanding COVID-19 vaccine efficacy Interim recommendations for use of the Pfizer-BioNTech COVID-19 vaccine Association of COVID-19 RT-qPCR test false-negative rate with patient age, sex and time since diagnosis Evaluation of COVID-19 RT-qPCR Test in Multi sample Pools